Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671.
Article
CAS
PubMed
PubMed Central
Google Scholar
Goto H, Prianti M. Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo. 2009;51:241–6.
Article
PubMed
Google Scholar
Md A, Ali N. Dynamicity of immune regulation during visceral leishmaniasis. Proc Indian Natl Sci Acad. 2014;80:247–67.
Article
Google Scholar
Bhattacharya P, Ali N. Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis. Rev Soc Bras Med Trop. 2013;46:128–34.
Article
PubMed
Google Scholar
Saha S, Mondal S, Banerjee A, Ghose J, Bhowmick S, Ali N. Immune responses in kala-azar. Indian J Med Res. 2006;123:245–66.
CAS
PubMed
Google Scholar
Mondal S, Bhattacharya P, Ali N. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther. 2010;8:919–44.
Article
PubMed
Google Scholar
Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, et al. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol. 2007;179:5592–603.
Article
CAS
PubMed
Google Scholar
Ejazi SA, Ali N. Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects. Expert Rev Anti Infect Ther. 2013;11:79–98.
Article
CAS
PubMed
Google Scholar
Bodhe PV, Kotwani RN, Kirodian BG, Pathare AV, Pandey AK, Thakur CP, et al. Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg. 1999;93:314–8.
Article
CAS
PubMed
Google Scholar
Mondal S, Bhattacharya P, Rahaman M, Ali N, Goswami RP. A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy. PLoS Negl Trop Dis. 2010;4:e764.
Article
PubMed
PubMed Central
Google Scholar
Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opin Pharmacother. 2005;6:2821–9.
Article
CAS
PubMed
Google Scholar
Timmers GJ, Zweegman S, Simoons-Smit AM, van Loenen AC, Touw D, Huijgens PC. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant. 2000;25:879–84.
Article
CAS
PubMed
Google Scholar
Pucadyil TJ, Tewary P, Madhubala R, Chattopadhyay A. Cholesterol is required for Leishmania donovani infection: implications in leishmaniasis. Mol Biochem Parasitol. 2004;133:145–52.
Article
CAS
PubMed
Google Scholar
Chandel AKS, Panthi B, Ranawat B. Impact of cholesterol on Leishmania parasites culture and in-vitro assessment of cytokine profile in Leishmania primed macrophage of healthy person. World J Pharm Pharm Sci. 2014;3:1567–84.
Google Scholar
Verma JN, Verma L, Tripathi KK. Sterol enriched mixed lamelarity amphotericin intercalating liposomes in saline and the process for their preparation. 2005. Patent Number WO/2005/120460.
Google Scholar
Mishra J, Dey A, Singh N, Somvanshi R, Singh S. Evaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model. Indian J Med Res. 2013;137:767–76.
CAS
PubMed
PubMed Central
Google Scholar
Afrin F, Ali N. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect Immun. 1997;65:2371–7.
CAS
PubMed
PubMed Central
Google Scholar
Banerjee A, De M, Ali N. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J Immunol. 2008;181:1386–98.
Article
CAS
PubMed
Google Scholar
Banerjee A, De M, Ali N. Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation. Antimicrob Agents Chemother. 2011;55:1661–70.
Article
CAS
PubMed
PubMed Central
Google Scholar
Roychoudhury J, Sinha R, Ali N. Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice. PLoS One. 2011;6:e17376.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kumar R, Nylen S. Immunobiology of visceral leishmaniasis. Front Immunol. 2012;3:251.
CAS
PubMed
PubMed Central
Google Scholar
Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs. 2008;17:787–94.
Article
CAS
PubMed
Google Scholar
Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011;377:477–86.
Article
CAS
PubMed
Google Scholar
Croft SL, Olliaro P. Leishmaniasis chemotherapy–challenges and opportunities. Clin Microbiol Infect. 2011;17:1478–83.
Article
CAS
PubMed
Google Scholar
Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995;13:527–37.
Article
CAS
PubMed
Google Scholar
Pandey K, Pun SB, Pandey BD. Relapse of kala-azar after use of multiple drugs: a case report and brief review of literature. Indian J Med Microbiol. 2012;30:227–9.
Article
CAS
PubMed
Google Scholar
Kumar N, Sinha PK, Pandey K, Verma N, Lal CS, Ranjan A, et al. A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy. Int J Clin Pharm. 2011;33:726–9.
Article
PubMed
Google Scholar
Meyerhoff A. U.S. Food and Drug Administration approval of Am Bisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis. 1999;28:42–8. discussion 49–51.
Article
CAS
PubMed
Google Scholar
Berman JD, Hanson WL, Chapman WL, Alving CR, Lopez-Berestein G. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother. 1986;30:847–51.
Article
CAS
PubMed
PubMed Central
Google Scholar
Szoka FC, mad Tang M. Liposome. J Liposome Res. 1993;3:363–75.
Article
CAS
Google Scholar
Hernandez G, Altermatt F, Bernucci F, Acuna D, Apablaza F, Valenzuela F, et al. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?]. Rev Med Chil. 2000;128:1101–7.
CAS
PubMed
Google Scholar
Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N, Rai M. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar. Trop Med Int Health. 2008;13:1208–12.
Article
CAS
PubMed
Google Scholar
Sachdeva H, Sehgal R, Kaur S. Asparagus racemosus ameliorates cisplatin induced toxicities and augments its antileishmanial activity by immunomodulation in vivo. Parasitol Int. 2014;63:21–30.
Article
CAS
PubMed
Google Scholar
Larabi M, Yardley V, Loiseau PM, Appel M, Legrand P, Gulik A, et al. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother. 2003;47:3774–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lanternier F, Lortholary O. Liposomal amphotericin B: what is its role in 2008? Clin Microbiol Infect. 2008;14 Suppl 4:71–83.
Article
CAS
PubMed
Google Scholar
Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis. 1996;22:938–43.
Article
CAS
PubMed
Google Scholar
Kushawaha PK, Gupta R, Tripathi CD, Sundar S, Dube A. Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis. PLoS One. 2012;7:e35670.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bogdan C. Natural killer cells in experimental and human leishmaniasis. Front Cell Infect Microbiol. 2012;2:69.
Article
PubMed
PubMed Central
Google Scholar
Ghalib HW, Whittle JA, Kubin M, Hashim FA, el-Hassan AM, Grabstein KH, et al. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol. 1995;154:4623–9.
CAS
PubMed
Google Scholar